1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Dengue Vaccine Market: Contribution of NGOs for Better Vaccine Access Expected to Drive the Market in Lower Income Countries: Global Industry Analysis & Opportunity Assessment, 2017 – 2027

Dengue Vaccine Market: Contribution of NGOs for Better Vaccine Access Expected to Drive the Market in Lower Income Countries: Global Industry Analysis & Opportunity Assessment, 2017 – 2027

  • March 2017
  • 98 pages
  • ID: 4911728
  • Format: PDF
  • By Future Market Insight Global & Consulting Pvt Ltd

Summary

Table of Contents

Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need

The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur is registered in 14 countries in the Latin America and Asia Pacific region. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines as well as subunit, DNA and purified inactivated vaccine candidates of which Takeda’s TAK-003 and Butantan Institute vaccine candidates are being evaluated in phase 3 clinical trials currently.

The global dengue vaccine market is estimated to be valued at nearly US$ 250 Mn in 2017 and is expected to expand at a 17.5% CAGR over the forecast period (2017–2027). The global dengue vaccine market is projected to be valued at more than US$ 1250 Mn by 2027.

Factors impacting the global dengue vaccine market
Growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, development of live attenuated tetravalent dengue vaccine, and expected local production of dengue vaccine in various countries. Other prominent factors driving revenue growth of the market are adoption/uptake of dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and increased governmental interest to incorporate the vaccine in public immunisation programmes across various countries.

However, supply side infrastructure bottlenecks such as surveillance system, standardised diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the factors hampering the growth of the global dengue vaccine market.

Companies engaged in the development of dengue vaccine are employing strategies to incorporate dengue vaccine in public immunisation programmes and vaccines in clinical stage development are being tested for safety and efficacy in all age groups and different transmission settings.

Global Dengue Vaccine Market Attractiveness Analysis by End User, 2017 – 2027
Several governments are willing to incorporate dengue vaccine in public immunisation programmes given assured quality, safety and affordability of the vaccine in endemic countries

The Government Institutes segment is expected to dominate the global dengue vaccine market in revenue terms and the trend is projected to continue throughout the forecast period. The Government Institutes segment is estimated to account for 49.5% value share in 2017 and is projected to account for 51.9% share by the end of 2027. In terms of value, the Hospitals segment is anticipated to register a moderate CAGR of 17.3% during the forecast period.

The NGOs segment is expected to remain the least attractive segment in the global dengue vaccine market in revenue terms with an attractiveness index of 0.7 over the forecast period. The NGOs segment is estimated to account for 22.5% value share in 2017 and is projected to account for 20.5% value share by the end of 2027. Analyst Viewpoint

Developing a vaccine that is effective in all age groups is expected to drive market revenue growth over the forecast period
Of late dengue vaccine candidates, which are in the late stage of development, are showing better clinical benefits in all age groups and have better dosing pattern. For instance, Takeda’s - Tak-003 dengue vaccine candidate has demonstrated acceptable safety and efficacy in different population groups with two doses (three months apart) of vaccine. Currently Dengvaxia is recommended in three doses at 0, 6, 12 months. Development of dengue vaccine that is effective for infants and children is expected to reduce the dengue burden and thereby create demand in the global dengue vaccine market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019SummaryHuman Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 9 molecules. Out of which approximately ...

Tuberculosis - Pipeline Review, H2 2019

Tuberculosis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Tuberculosis - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H2 2019, provides an overview of the Tuberculosis (Infectious ...

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2019

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on